摘要
近年来,随着直接抗病毒药物(direct-acting antiviral drugs,DAAs)第一代NS3/4A蛋白酶抑制剂的上市,源源不断DAAs新药临床研究结果的公布及DAAs新药的陆续上市,为丙型肝炎的治疗带来了革命性的变化,一个DAAs时代已经来到。WHO首次发布了丙型肝炎防治指南,美国及欧洲肝病学会在线也及时更新了慢性丙型肝炎治疗的推荐意见。本文对慢性丙型肝炎的治疗进展及展望进行简述。
In recent years, with the approval of direct-acting antiviral agents （DAAs） against the NS3/4A serine protease for use, the publishing of the results of clinical research on novel DAAs, and the approval of novel DAAs for use, a dramatical change in treatment of hepatitis C has taken place, and a new era of hepatitis C therapy with DAAs has begun. World Health Organization issued its first global hepatitis C treatment guidelines. American Association for the Study of Liver Diseases and European Associa-tion for the Study of the Liver issued updated recommendations on treatment of hepatitis C online in time. This review focuses on the recent advances and future prospects in treatment of chronic hepatitis C.
出处
《传染病信息》
2014年第4期193-197,共5页
Infectious Disease Information
基金
国家"十二五"科技重大专项(2012ZX1005-005)
关键词
丙型肝炎
慢性
干扰素类
酶抑制剂
hepatitis C,chronic
interferons
enzyme inhibitors
